



SEQUENCE LISTING

<110> THERAPTOSIS S.A.

<120> Peptides having, for example, an antiangiogenic activity and applications thereof in therapeutics

<130> 1721-112

<140> 10/573,576

<141> 2006-03-24

<150> PCT/FR04/02422

<151> 2004-09-24

<150> FR 02 11 270

<151> 2003-09-25

<160> 30

<170> PatentIn version 3.1

<210> 1

<211> 26

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa=G

<220>

<221> MISC_FEATURE

<222> (2)..(2)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=C, A, D, Q or N

<220>

<221> MISC_FEATURE

<222> (17)..(17)

<223> Xaa= R or K

<220>
<221> MISC_FEATURE
<222> (21)..(21)
<223> Xaa= R or K

<220>
<221> MISC_FEATURE
<222> (24)..(24)
<223> Xaa= R or K

<220>
<221> MISC_FEATURE
<222> (26)..(26)
<223> Xaa=G, A, V, L or I

<400> 1
Xaa Xaa Arg Gly Asp Xaa Phe Gly Xaa Xaa Leu Leu Phe Ile His Phe
1 5 10 15

Xaa Ile Gly Ser Xaa His Ser Xaa Ile Xaa
20 25

<210> 2
<211> 28
<212> PRT
<213> Human HIV

<400> 2
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 3
<211> 28
<212> PRT
<213> Human HIV

<400> 3
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 4
<211> 27
<212> PRT
<213> Human HIV

<400> 4

Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 5
<211> 28
<212> PRT
<213> Human HIV

<400> 5
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 6
<211> 28
<212> PRT
<213> Human HIV

<400> 6
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 7
<211> 29
<212> PRT
<213> Human HIV

<400> 7
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Asn Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 8
<211> 28
<212> PRT
<213> Human HIV

<400> 8
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 9
<211> 28

<212> PRT
<213> Human HIV

<400> 9
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Ser Ile
1 5 10 15
His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 10
<211> 28
<212> PRT
<213> Human HIV

<400> 10
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Arg
1 5 10 15
His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 11
<211> 6
<212> PRT
<213> Human HIV

<400> 11
Arg Gly Asp Met Phe Gly
1 5

<210> 12
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 12
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15
His Phe Arg Ile Gly Cys Arg His Ser Arg Ile Gly
20 25

<210> 13

<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 13
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

Phe Phe Arg Ile Gly Cys Arg Phe Ser Arg Ile Gly
20 25

<210> 14
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 14
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 15
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 15

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Arg Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 16

<211> 27

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 16

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 17

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 17

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Ser Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 18

<211> 28

<212> PRT

<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 18
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Lys Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 19
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 19
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 20
<211> 28
<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 20

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 21

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 21

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Ser Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 22

<211> 28

<212> PRT

<213> Human HIV

<220>

<221> MISC_FEATURE

<222> (3)..(3)

<223> Xaa=amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> Xaa=amino acid

<400> 22

Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Arg
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 23

<211> 28

<212> PRT
<213> Human HIV

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa=amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> Xaa=amino acid

<400> 23
Gly Gly Xaa Arg Gly Asp Met Phe Gly Xaa Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 24
<211> 28
<212> PRT
<213> Human HIV

<400> 24
Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 25
<211> 28
<212> PRT
<213> Human HIV

<400> 25
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly Leu Leu Phe Ile
1 5 10 15

His Phe Ala Ile Gly Ser Arg His Ser Ala Ile Gly
20 25

<210> 26
<211> 27
<212> PRT
<213> Human HIV

<400> 26
Arg Lys Lys Arg Arg Gln Arg Arg Arg Gly Gly Leu Leu Phe Ile His
1 5 10 15

Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
20 25

<210> 27
<211> 16
<212> PRT
<213> Human HIV

<400> 27
Leu Leu Phe Ile His Phe Arg Ile Gly Ser Arg His Ser Arg Ile Gly
1 5 10 15

<210> 28
<211> 12
<212> PRT
<213> Human HIV

<400> 28
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 29
<211> 12
<212> PRT
<213> Human HIV

<400> 29
Gly Gly Cys Arg Ala Asp Met Phe Gly Cys Gly Gly
1 5 10

<210> 30
<211> 12
<212> PRT
<213> Human HIV

<400> 30
Gly Gly Cys Arg Gly Asp Met Phe Gly Cys Gly Gly
1 5 10